It is with great pleasure that we announce the relaunch of our corporate brand and website. The brand design has been refined and updated to reflect AudioCure’s innovative and forward-thinking outlook. Meanwhile, we hope that with its clear structure, easy navigation...
AudioCure Pharma GmbH secures funding of about EUR 9 Million for the further development of their lead candidate, AC102, in hearing loss. Austrian company MED-EL Elektromedizinische Geräte GmbH (MED-EL), Innsbruck, the technology leader in implantable hearing...
Following extensive preclinical research, AudioCure Pharma has selected AC102 as its candidate for clinical development. Our next step will be to bring AC102 into the so-called formal preclinical stage of development, a prerequisite for the initiation of clinical...
We are very pleased to announce the start of our collaboration with Dr. Julian Hellmann-Regen, Head of the Clinical Neurobiology Laboratory at the Charité Universitätsmedizin, Berlin. Dr. Hellmann and his team will further investigate the molecular mode of action of...
We are happy to announce that Dr. Reimar Schlingensiepen has joined AudioCure as COO. Dr. Schlingensiepen is an experienced entrepreneur and manager for biotech, medtech and diagnostics companies. He offers his leadership expertise in the multiple fields of the...
AudioCure strives to protect its successful drug research by international patents. We are therefore very pleased, that the priority year of the Composition of Matter Patent „Fluorcarboline“ ended on September 29th. At the same time a supplemented version in the form...
